← All trials
NCT06588517
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2024
- Primary completion
- Apr 19, 2024
- Completion date
- Apr 27, 2024
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Overseas Pharmaceuticals, Ltd.Lead sponsor
- Shanghai ShouYan Clinical Development Co.,Ltd.Collaborator
- Qingdao UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.